Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management
Access to genomic testing, not therapy cost, is the biggest challenge
30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
Subscribe To Our Newsletter & Stay Updated
